Quince Therapeutics, Inc. (QNCX)
31.32
+0.77
(+2.52%)
USD |
NASDAQ |
Sep 04, 16:00
31.18
-0.14
(-0.43%)
After-Hours: 20:00
Quince Therapeutics Shareholders Equity (Quarterly) : 108.49M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 108.49M |
| March 31, 2026 | 15.67M |
| December 31, 2025 | -35.71M |
| September 30, 2025 | 1.059M |
| June 30, 2025 | 11.74M |
| March 31, 2025 | 18.58M |
| December 31, 2024 | 30.15M |
| September 30, 2024 | 44.93M |
| June 30, 2024 | 46.97M |
| March 31, 2024 | 74.18M |
| December 31, 2023 | 85.08M |
| September 30, 2023 | 83.13M |
| June 30, 2023 | 86.88M |
| March 31, 2023 | 90.20M |
| December 31, 2022 | 100.59M |
| Date | Value |
|---|---|
| September 30, 2022 | 104.53M |
| June 30, 2022 | 111.53M |
| March 31, 2022 | 106.38M |
| December 31, 2021 | 118.59M |
| September 30, 2021 | 132.65M |
| June 30, 2021 | 142.08M |
| March 31, 2021 | 156.48M |
| December 31, 2020 | 172.26M |
| September 30, 2020 | 188.01M |
| June 30, 2020 | 205.47M |
| March 31, 2020 | 218.04M |
| December 31, 2019 | 115.48M |
| September 30, 2019 | 127.29M |
| June 30, 2019 | 136.22M |
| March 31, 2019 | 66.11M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.528B |
| Anixa Biosciences, Inc. | 14.48M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 124.00M |
| Total Liabilities (Quarterly) | 15.51M |
| Current Ratio | 14.52 |
| Net Debt Paydown Yield | 17.03% |